Research programme: monoPARP inhibitors - Ribon Therapeutics
Alternative Names: PARP7 inhibitors - Ribon TherapeuticsLatest Information Update: 28 Feb 2023
At a glance
- Originator Ribon Therapeutics
- Class Anti-inflammatories; Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Neurodegenerative disorders
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Feb 2023 No recent reports of development identified for research development in Inflammation in USA
- 28 Feb 2023 No recent reports of development identified for research development in Neurodegenerative-disorders in USA